Who owns Roivant Sciences Ltd.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ROIV from SEC Form 13F filings across 498 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 498 institutions disclosed 556.6M shares of Roivant Sciences Ltd. worth $19.70B — about 77.2% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
498
13F holders
$19.70B
value, 2026 filers
77.2%
of shares outstanding (556.6M sh)
108
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of ROIV's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 81.0M | $2.87B | 0.1% | 11.2% | +3.9% |
| 2 | BlackRock, Inc. | 48.2M | $1.71B | 0.0% | 6.7% | +9.0% |
| 3 | MORGAN STANLEY | 42.6M | $1.51B | 0.1% | 5.9% | -17.8% |
| 4 | QVT Financial LP | 23.7M | $839.6M | 49.4% | 3.3% | -5.7% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 22.1M | $782.9M | 0.0% | 3.1% | +7.0% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 21.6M | $765.9M | 0.0% | 3% | +9.1% |
| 7 | GOLDMAN SACHS GROUP INC | 18.6M | $656.7M | 0.1% | 2.6% | +67.0% |
| 8 | STATE STREET CORP | 17.8M | $629.8M | 0.0% | 2.5% | +9.9% |
| 9 | UBS Group AG | 17.5M | $618.1M | 0.1% | 2.4% | -22.8% |
| 10 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 14.3M | $506.4M | 2.3% | 2% | +47.9% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 11.7M | $425.5M | 0.0% | 1.6% | +14.7% |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 10.3M | $366.3M | 0.5% | 1.4% | -19.1% |
| 13 | Two Seas Capital LP | 8.5M | $299.9M | 5.9% | 1.2% | -9.1% |
| 14 | Assenagon Asset Management S.A. | 8.4M | $296.0M | 0.4% | 1.2% | +18.2% |
| 15 | PERCEPTIVE ADVISORS LLC | 8.1M | $286.1M | 4.3% | 1.1% | -2.4% |
| 16 | Patient Square Capital LP | 8.0M | $283.9M | 44.0% | 1.1% | -1.8% |
| 17 | Invesco Ltd. | 7.5M | $266.5M | 0.0% | 1% | +17.0% |
| 18 | Darwin Global Management, Ltd. | 6.7M | $234.3M | 6.2% | 0.9% | -0.7% |
| 19 | AQR CAPITAL MANAGEMENT LLC | 6.6M | $234.0M | 0.1% | 0.9% | +11.5% |
| 20 | VIKING GLOBAL INVESTORS LP | 6.3M | $221.9M | 0.6% | 0.9% | -5.7% |
| 21 | Rubric Capital Management LP | 6.0M | $212.3M | 1.9% | 0.8% | +20.0% |
| 22 | CITADEL ADVISORS LLC | 5.6M | $197.3M | 0.0% | 0.8% | +121.6% |
| 23 | DIMENSIONAL FUND ADVISORS LP | 5.2M | $185.1M | 0.0% | 0.7% | -30.0% |
| 24 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.8M | $170.5M | 0.0% | 0.7% | -31.1% |
| 25 | NORGES BANKNEW | 4.7M | $168.0M | 0.0% | 0.7% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.